Literature DB >> 6742979

Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up.

W Coryell, P Lavori, J Endicott, M Keller, M VanEerdewegh.   

Abstract

In the National Institute of Mental Health Collaborative Study of the Psychobiology of Depression, six-month follow-up evaluations are available for 24 patients with schizoaffective disorder (depressed type), 56 with psychotic depression, and 274 with nonpsychotic major depression. Outcome for patients with schizoaffective depression was significantly worse than for patients with nonpsychotic depression. The psychotic depression group held an intermediate position on most outcome measures and on psychosocial measures had outcomes significantly worse than those of the nonpsychotic group. Recovery rates assumed a very similar pattern in another cohort admitted more than 40 years ago and followed up without somatic treatment. Follow-ups of 12, 18, and 24 months are available for proportions of each diagnostic group. Survival curves suggest similar outcomes in psychotic depression and nonpsychotic depression, whereas outcomes in schizoaffective depression remain disparate. These trends together with family history studies suggest that a small proportion of patients with schizoaffective disorder, depressed type, will have a long-term course consistent with schizophrenia. Moreover, these data show that outcome studies of schizoaffective disorder must control for follow-up length and the effects of psychosis per se.

Entities:  

Mesh:

Year:  1984        PMID: 6742979     DOI: 10.1001/archpsyc.1984.01790190061008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

1.  Prediction of vocational outcome based on clinical and demographic indicators among vocationally ready clients.

Authors:  E S Rogers; W A Anthony; M Cohen; R R Davies
Journal:  Community Ment Health J       Date:  1997-04

2.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

Review 3.  Unique issues in assessing work function among individuals with psychiatric disabilities.

Authors:  K MacDonald-Wilson; E S Rogers; W A Anthony
Journal:  J Occup Rehabil       Date:  2001-09

4.  Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care.

Authors:  Maju Mathew Koola; Jan A Fawcett; Deanna L Kelly
Journal:  J Nerv Ment Dis       Date:  2011-12       Impact factor: 2.254

5.  Relationship of electroconvulsive therapy to course in affective illness: a collaborative study.

Authors:  G Winokur; W Coryell; M Keller; W A Scheftner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

6.  Prevalence and clinical characteristics of psychotic versus nonpsychotic major depression in a general psychiatric outpatient clinic.

Authors:  Brandon A Gaudiano; Kristy L Dalrymple; Mark Zimmerman
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

7.  Schizo-affective psychoses in childhood: a follow-up study.

Authors:  C Eggers
Journal:  J Autism Dev Disord       Date:  1989-06

Review 8.  Clinical and molecular genetics of psychotic depression.

Authors:  Katharina Domschke
Journal:  Schizophr Bull       Date:  2013-03-19       Impact factor: 9.306

Review 9.  Does Biology Transcend the Symptom-based Boundaries of Psychosis?

Authors:  Godfrey D Pearlson; Brett A Clementz; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga
Journal:  Psychiatr Clin North Am       Date:  2016-02-28

10.  The clinical relevance of gray matter atrophy and microstructural brain changes across the psychosis continuum.

Authors:  Faith M Hanlon; Andrew B Dodd; Josef M Ling; Nicholas A Shaff; David D Stephenson; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Sephira G Ryman; Andrew R Mayer
Journal:  Schizophr Res       Date:  2021-02-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.